



Universiteit
Leiden
The Netherlands

The glyocalyx: a diagnostic and therapeutic target in cardiometabolic diseases

Velden, A.I.M. van der

Citation

Velden, A. I. M. van der. (2024, September 3). *The glyocalyx: a diagnostic and therapeutic target in cardiometabolic diseases*. Retrieved from <https://hdl.handle.net/1887/4039604>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4039604>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER 4

Role of dietary interventions on microvascular health in South-Asian Surinamese people with type 2 diabetes in the Netherlands; a randomized controlled trial

Anouk I.M. van der Velden
Daphne H.T. Ijpelaar
Prataap K. Chandie Shaw
Hanno Pijl
Hans Vink
Johan van der Vlag
Ton J. Rabelink*
Bernard M. van den Berg*
* Share last authorship

Nutrition and Diabetes
2024, 14:17

Abstract

Background: We investigated whether dietary interventions, i.e. a fasting mimicking diet (FMD, Prolon®) or glycocalyx mimetic supplementation (Endocalyx™) could stabilize microvascular function in Surinamese South-Asian patients with type 2 diabetes (SA-T2DM) in the Netherlands, a patient population more prone to develop vascular complications.

Methods: A randomized, placebo controlled, 3-arm intervention study was conducted in 56 SA-T2DM patients between 18 and 75 years old, for 3 consecutive months, with one additional follow up measurement 3 months after the last intervention. Sublingual microcirculation was assessed with SDF-imaging coupled to the GlycoCheck™ software, detecting red blood cell velocity, capillary density, static and dynamic perfused boundary region (PBR), and the overall microvascular health score (MVHS). Linear mixed models and interaction analysis were used to investigate the effects the interventions had on microvascular function.

Results: Despite a temporal improvement in BMI and HbA1c after FMD the major treatment effect on microvascular health was worsening for RBC-velocity independent $PBR_{dynamic}$, especially at follow-up. Glycocalyx supplementation, however, reduced urinary MCP-1 presence and improved both $PBR_{dynamic}$ and $MVHS_{dynamic}$, which persisted at follow-up.

Conclusions: We showed that despite temporal beneficial changes in BMI and HbA1c after FMD, this intervention is not able to preserve microvascular endothelial health in Dutch South-Asian patients with T2DM. In contrast, glycocalyx mimetics preserves the microvascular endothelial health and reduces the inflammatory cytokine MCP-1.

Introduction

Diabetic vascular complications account for an enormous health burden worldwide with various ethnic groups that are more prone to develop such vascular complications [1, 2]. In the Netherlands, people from South-Asian Surinamese descent are characterized by such high vascular vulnerability, resulting in increased prevalence of micro- and macrovascular complications in diabetes [3-5]. At time of diagnosis these higher rates of complications are already found [3, 6, 7] and progression is also much faster compared to other ethnic groups, translating into a 40 times higher risk for end stage renal disease [8] and a 50% higher age-adjusted mortality rate from coronary heart disease [9].

One of the first hallmarks of vascular damage is endothelial dysfunction, which can progress to structural microvascular changes, and eventually result in irreversible vascular damage [10-14]. Upregulation of glycocalyx degrading enzymes and inflammatory cytokines such as heparanase-1 (HPSE-1) and monocyte chemoattractant-1 (MCP-1) augments endothelial dysfunction by impairing the endothelial glycocalyx (EG), a mesh of glycosaminoglycans (GAGs), proteoglycans, glycoproteins and glycolipids on the apical side of endothelial cells [15]. Next to conventional therapeutic options, preserving endothelial function in South Asian patients with T2DM (SA-T2DM) could prevent or reduce the fast progression of vascular complications through inhibiting glycocalyx degrading enzymes or reducing metabolic risk factors that contribute to glycocalyx degradation.

Intermittent fasting or fasting mimicking diets (FMD) have been shown to be able to induce cellular changes that affect inflammation and cellular protection [16-21]. A study of T2DM patients with micro-albuminuria showed that FMD could be conducted safely and showed beneficial effects on albuminuria [22]. Recently, we revealed in an experimental diabetic study that repeated FMD partially preserved the glomerular endothelial glycocalyx coverage, however, perturbing glomerular metabolic responses [23]. Also a new promising dietary intervention through supplementation with GAGs mimetics such as fucoidan, a marine organism-derived fucosylated and sulfated polysaccharide and major constituent of EndocalyxTM, has been shown to preserve the EG layer [24, 25].

Here, we investigated the effects of these two dietary interventions, repeated FMD cycles or EndocalyxTM supplementation in SA-T2DM in a multi-arm randomized controlled study. We hypothesized that these dietary interventions are able to preserve endothelial stability and in turn preserve microvascular health.

For this, microvascular health was assessed on the sublingual microvasculature with the non-invasive sidestream dark field (SDF) imaging method with newly developed and validated GlycocheckTM software [26, 27]. In addition, besides demographics, medication

use, blood pressure and laboratory markers for diabetes and renal function testing, we measured the HPSE-1 and hyaluronidase 1 (HYAL-1) activity, and HYAL-4 activity and concentration, together with the endothelial activation markers angiotensin-2 (ANG2), soluble thrombomodulin (sTM) and MCP-1.

Research design and methods


Clinical study design and patient recruitment

We conducted a multi-arm parallel-group randomized study in SA-T2DM of Surinamese descent in The Hague area of the Netherlands between May 2018 and September 2020, recruited at general practitioners' offices. In this study 3 parallel arms were selected: 1) receiving a diet regime of FMD boxes (Prolon®, L-Nutra Inc., Los Angeles, CA, USA); 2) receiving the dietary supplement Endocalyx™ (MicroVascular Health Solutions LLC, Alpine, UT, USA); or 3) receiving placebo capsules (figure 1A). For sample size estimation the primary outcome was determined as improvement of the Microvascular Health Score (MVHS_{dynamic}) according to a pilot study with 13 healthy volunteers receiving the food supplement Endocalyx™ for 3 consecutive months (supplemental figure 1). Eligible patients, with inclusion criteria of age between 18 and 75 years old, self-identified as from South-Asian Surinamese descent, treatment with hypoglycemic drugs for type 2 diabetes and proven albuminuria with an albumin to creatinine ratio (ACR) between 0.3 and 30 mg/mmol in the last 12 months. Moreover, eGFR had to be above 45 mL/min/1.73 m² (CKD-EPI formula [28]). The study (NCT03889236) was conducted in accordance with the Declaration of Helsinki (October 2013) and approved by the Ethics Committee of the Leiden University Medical Center (LUMC) in agreement with the Dutch law for medical research involving human subjects.

Intervention, randomization and blinding

Eligible patients were randomized via randomization envelopes made by the Pharmacy department of the LUMC into the diet-, supplement-, or placebo-arm, after given informed consent (figure 1). In agreement with the CONSORT statement, randomisation was performed to provide blinding of the supplement and placebo arm to the participants, care providers and researchers. The Pharmacy department redistributed, labeled and blinded the capsules.

The FMD (Prolon®) consisted of a 5-day low protein plant-based diet regime that contained energy bars, vegetable-based soups, kale chips, olives, energy drinks, a supplement and natural tea's. Day 1 provided 1,090 kcal (containing 34% carbohydrate, 56% fat and 10% protein), and days 2 to 5 were identical in formulation and provided 725 kcal (47% carbohydrate, 44% fat and 9% protein). As previous studies with this diet showed benefi-



cial effects after 3 monthly cycles [16], our patients also followed the diet once a month, with a total of 3 cycles in 3 months. Trajectory patients' satisfaction about FMD intervention was reviewed with the Diabetes Treatment Satisfaction Questionnaire (DTSQ) [29]. EndocalyxTM supplement was produced and provided by Microvascular Health Solutions (Alpine, UT, USA). One capsule contained fucoidan extracted from *Laminaria japonica* (106.25 mg), glucosamine sulphate (375.0 mg), hyaluronic acid (17.5 mg), a blend of superoxide dismutase and polyphenols (120.0 mg) and stabilizers/bulking agents. The placebo capsules were manufactured by the Pharmacy department of the LUMC and contained microcrystalline cellulose. Patients were instructed to take 4 capsules a day for 3 consecutive months. Patients received no dietary advice and maintained their normal diet during the study.

Data collection

Study visits were conducted at the general practitioner's office of that specific patient and were executed by the researcher or research assistants. The web based relational database management system Castor Electronic Data Capture (EDC) (<https://www.castoredc.com>) was used for data storage. Patients were instructed to fast overnight and not to smoke before each study visit. In the first three months, patients had a study visit each month. After completing the first 3 months of the intervention, the interventions were discontinued, and patients had one follow-up study visit at month 6 (figure 1A).

At baseline, self-identified ethnicity, age and smoking status were collected. Medical history and medication use was extracted from the personal health records. Microvascular complications were defined as having retinopathy and/or neuropathy. Macrovascular complications were defined as having myocardial infarction, angina pectoris, cerebrovascular accident and/or peripheral artery disease.

Systolic and diastolic BP was measured twice with an automated blood pressure monitor (OMRON, Model M6, Omron Health Care Inc, IL, USA) after patients were sitting calmly for about 5 minutes. BMI was calculated by dividing the weight (measured with indoor clothing but without shoes) in kilograms by the self-reported height in meters squared. Waist circumference was measured with a measuring tape mid-way between the lower costal margin and the iliac crest. Fasting blood glucose levels were measured with a finger prick blood sample (Accu-chek Aviva, Roche, Basel, Swiss).

Blood samples were collected after overnight fast at the morning of the study visit at baseline, 3- and 6 months through vena puncture. Serum levels of C-peptide, Insulin growth factor 1 (IGF-1), creatinine, high sensitivity C-reactive protein (HsCRP), total cholesterol, high-density lipoprotein cholesterol, triglycerides levels and plasma levels of HbA1c were determined in the central clinical chemistry laboratory of the LUMC using standard assays.

Low-density lipoprotein cholesterol was calculated using the Friedewald formula [30]. The CKD-EPI formula was used to estimate the glomerular filtration rate [28].

Plasma HPSE-1 (heparan sulfate, HS degradation) activity (Takara Bio Inc., Shiga, Japan), HYAL-1 [31] (chondroitin sulfate/hyaluronan, CS/HA) and HYAL-4 [32] (CS) activity in-house developed ELISA [33], optimized by use of recombinant active human HYAL-1 or HYAL-4 (7358-GH-020 and #6904-GH-020, Bio-techne, Abingdon, UK). HYAL-4 protein was measured (AMS Biotechnology, Abingdon, UK) according to the manufacturer's instructions. Plasma levels of ANG2 (DANG20, R&D Systems, Abington, UK) and sTM (850.720.096, Diacnone, Besançon, France) were determined as described [32], and measured according to the protocol supplied by the manufacturer.

On the day of study visit, first morning urine was collected to determine albumin and creatinine (CCL, LUMC), albumin-creatinine ratio (ACR) was calculated and for albumin levels lower than 3.0 mg/mL (displayed as <3.0 by CCL), 2.9 was used for ACR calculation. Urinary HPSE-1 activity and MCP-1 concentration were measured (Takara Bio Inc., Shiga, Japan and R&D Systems Europe, Ltd., Abingdon, UK, resp.) according to manufacturer's protocols and corrected for creatinine concentration.

Microvascular imaging

Sublingual microcirculation was assessed with SDF-imaging (CapiScope HVCS, KK Technology, Honiton, UK) coupled to the GlycoCheck™ software (Microvascular Health Solutions Inc., Salt Lake City, UT, USA). Image acquisition was automatically mediated through the Glycocheck™ software as described elsewhere [26, 27, 34]. The GlycoCheck™ software detects and extracts the following microvascular parameters: red blood cell velocity (V_{RBC}), perfused capillary density, static and dynamic capillary blood volume (CBV), static and dynamic perfused boundary region (PBR), and the overall microvascular health score (MVHS), validated and described earlier [27, 35].

Glucose monitoring and diet compliance

To minimize the occurrence of hypoglycemia during the diet cycles, dosages of hypoglycemic medications were temporarily altered during the 5 day diet cycle. Sulfonylurea derivatives and short acting insulin were discontinued, long acting insulin reduced by 50%, with fasting glucose monitoring on days 6, 7 and 8. Metformin, DPP-4 inhibitors, SGLT-2 inhibitors or GLP-1 agonists were continued during the diet cycle. Compliance was checked on the morning of day 5 of the first FMD cycle by measuring fasting ketone body concentration in blood (CareSens Dual, Zkope Healthcare, Sittard, Netherlands) and with ketone sticks in a fresh morning urine sample (Ketostix, Bayer, Leverkusen, Germany). During the cycles patients were contacted by the investigator to check glucose monitoring and compliance with the diet.

Clinical data and resource availability

Most of the data generated or analyzed during this study are included in the published article (and its online supplementary files). The remainder clinical data generated during and/or analyzed during the current study are not publicly available due to hospital privacy restrictions but can be made available as anonymized data from the corresponding author upon reasonable request.

Statistical analysis

The primary endpoint was improvement of microvascular function within 3 months as determined with SDF-imaging (capillary density, CBV, PBR and MVHS). Secondary endpoints were improvement in clinical parameters (BP, BMI, waist-to-hip ratio), laboratory markers (ACR, fasting glucose, HbA1c, C-peptide, IGF-1, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, hsCRP, HPSE-1, HYAL-1, HYAL-4, ANG2, sTM and MCP-1). Potential legacy effects were determined using the microvascular and clinical parameters, 3 months after discontinuation (at month 6).

Continuous variables with normal distribution were presented as mean with standard deviation (SD) and variables with skewed distribution as median with 25-75 percentile. Categorical data were expressed as proportions.

Treatment effects within and between groups (diet vs. placebo and supplement vs. placebo, respectively) were investigated with intention to treat analysis by linear mixed models for repeated measurements with Bonferroni post hoc test (values expressed as estimated marginal means (SE) or estimated mean differences with 95% CI). The models were adjusted for age, gender, microvascular and macrovascular history at baseline and hypertension at baseline as this can influence microvascular function. For the per protocol analysis, delta changes within 3 months intervention were compared between the intervention groups with an unpaired t-test.

Results from the DTSQ questionnaire (see supplemental data) were compared between FMD and placebo groups with an unpaired t-test.

Statistical analysis was performed using SPSS version 25 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism version 8 (Graphpad Inc., La Jolla, CA, USA). A significance level of 0.05 was considered statistically significant.

Results

Inclusion and drop-outs

A total of 56 patients were included and randomized (see CONSORT diagram in figure 1), with 19 patients in the diet group, 19 in the supplement group and 18 patients in the placebo group. In the diet group, one patient withdrew due to pregnancy at the start of the study and one patient withdrew during the baseline visit due to anxiety for the venipunctures. 3 Patients discontinued due to adverse events or non-adherence during or after the first diet cycle and one patient was withdrawn by the investigator due to an SAE after the first diet cycle. A total of 13 patients completed the 3 diet cycles and the follow-up study visit at month 6 (figure 1). In the supplement group, 19 patients were randomized and completed the baseline measurement. One patient did not start due to the COVID-19 pandemic, which resulted in 18 patients completing the 3-month intervention and follow-up. In the placebo group, 2 patients withdrew informed consent before the baseline visit and one patient was withdrawn by the investigator after the baseline measurements due to an eGFR below the inclusion criteria threshold. A total of 15 patients completed the 3 months placebo intervention and 14 patients completed the follow-up study visit at month 6, as one patient migrated to Surinam. Due to the COVID-19 pandemic all inclusions had to stop, preventing completion of the estimated number of patients per group.

Baseline characteristics of the study population

Baseline characteristics of FMD- (n=18), Endocalyx- (n=19) and placebo group (n=16) and total cohort (n=53) are shown in Table 1. Overall, baseline characteristics were almost similar between both dietary intervention groups and placebo group, except mean age in

Table 1. Baseline characteristics of the study population

	Placebo (n=16)	Diet (n=18)	Supplement (n=19)	Total (n=53)
Demographics				
Age, years (SD)	63 (±7)	61 (±6)	56 (±7)	60 (±7)
Women, n (%)	7 (44)	12 (67)	12 (63)	31 (59)
Current tobacco smoking, n (%)	5 (31)	4 (22)	6 (32)	15 (28)
Medical history				
Duration diabetes mellitus, years (SD)	7 (±5)	11 (±4)	9 (±5)	9 (±5)
Retinopathy, n (%)	4 (25)	10 (56)	5 (26)	19 (36)
Neuropathy, n (%)	1 (6)	2 (11)	4 (21)	7 (13)
Coronary artery disease, n (%)	4 (25)	3 (16)	2 (11)	9 (17)
Angina pectoris, n (%)	4 (25)	2 (11)	1 (5)	7 (13)
CVA/TIA, n (%)	3 (19)	0	4 (21)	7 (13)

Table 1. Baseline characteristics of the study population (*continued*)

	Placebo (n=16)	Diet (n=18)	Supplement (n=19)	Total (n=53)
Medication use				
Metformin, n (%)	16 (100)	17 (94)	19 (100)	52 (98)
DPP-4 inhibitor/GLP-1-RA/SGLT2 antagonist, n (%)	2 (13)	3 (17)	3 (16)	8 (15)
Sulfonylurea derivatives, n (%)	3 (19)	9 (50)	9 (47)	21 (40)
Insulin, n (%)	2 (13)	3 (17)	3 (16)	8 (15)
Anti-hypertensive medication, n (%)	11 (61)	12 (67)	12 (63)	35 (66)
RAAS inhibitors (n)	10 of 11	10 of 12	10 of 12	30 of 35
Statins, n (%)	12 (75)	16 (89)	16 (84)	44 (83)
Blood pressure				
Systolic blood pressure, mmHg (SD)	139 (±16)	148 (±19)	132 (±15)	140 (±18)
Diastolic blood pressure, mmHg (SD)	86 (±9)	87 (±10)	82 (±11)	85 (±10)
Hypertension, n (%)	13 (72)	16 (89)	11 (58)	40 (76)
BMI, kg/m ² (SD)	27.4 (±4.3)	28.8 (±5.5)	30.1 (±4.7)	28.8 (±4.9)
Laboratory markers				
Fasting glucose, mmol/L (range)	7.3 (±1.6)	7.6 (±1.7)	8.3 (±2.2)	7.8 (±1.9)
HbA1c, % (range) / mmol/mol (range)	6.8 (6.5-8.0) / 51 (47-63)	7.2 (7.0-7.7) / 56 (50-60)	7.2 (6.8-7.9) / 56 (51-62)	7.2 (6.7-7.8) / 55 (50-61)
Total cholesterol, mmol/L (SD)	3.9 (±0.7)	4.4 (±0.8)	4.4 (±1.1)	4.3 (±0.9)
hsCRP, mg/L (range)	1.6 (0.8-5.2)	2.1 (0.9-5.0)	4.7 (2.9-8.1)	3.2 (1.0-4.7)
eGFR CKD-EPI (ml/min/1.73m ²)	80 (±17)	84 (±19)	85 (±19)	83 (±18)
Urinary markers				
Albumin/creatinine ratio (mg/mmol)	1.8 (0.9-3.2)	1.0 (0.6-1.6)	1.0 (0.6-3.9)	1.1 (0.6-2.4)
Normo-albuminuria ^b , (n, %)	9 (56)	17 (94)	15 (79)	41 (77)
Micro-albuminuria at baseline ^c , (n, %)	7 (44)	0 (0)	3 (16)	10 (19)
Macro-albuminuria at baseline ^d , (n, %)	0 (0)	1 (6)	1 (5)	2 (4)

Data is presented as mean (SD), median (25-75 percentile) or number with percentage.

Abbreviations: CVA/TIA cerebrovascular event/transient ischemic attack, DPP-4 dipeptidyl peptidase-4, GLP-1-RA glucagon-like peptide-1 receptor agonist, SGLT2 sodium-glucose cotransporter 2, RAAS renin-angiotensin-aldosterone system, BMI body mass index, HbA1c hemoglobin A1c, hsCRP high sensitivity c-reactive protein, eGFR CKD-EPI estimated glomerular filtration rate according to chronic kidney disease epidemiology collaboration

^aAccording to the AHA guidelines ≥ 130 mmHg systolic or ≥ 80 mmHg diastolic

^bAlbumin-creatinine ratio between <3.0 mg/mmol ^cAlbumin-creatinine ratio between $3.0 - 30$ mg/mmol ^dAlbumin-creatinine ratio > 30 mg/mmol.

Endocalyx group was younger and mean duration of diabetes mellitus was higher in FMD group compared to placebo group. Several patients in all groups had prevalent micro- or macrovascular diabetes complications. All patients used various combinations anti-diabetes medication. More than half of the patients used antihypertensive medication,

of which a large number used renin-angiotensin-aldosterone system (RAAS) inhibitors. Despite this, percentage of patients with hypertension (according to the AHA guidelines ≥ 130 mmHg systolic or ≥ 80 mmHg diastolic) was around 89% (FMD), 58% (Endocalyx) and 72% (placebo). Mean BMI was high in all groups, $28.8 \pm 5.5 \text{ kg/m}^2$ (FMD), $30.1 \pm 4.7 \text{ kg/m}^2$ (Endocalyx) and $27.4 \pm 4.3 \text{ kg/m}^2$ (placebo). In general, patients were well regulated as reflected by the average low HbA1c levels. The placebo group had the highest number of patients with albuminuria in the past 12 months ($n=7$) compared to FMD ($n=1$) and Endocalyx ($n=4$).

Microvascular health in placebo group

First, when combining all baseline data (FMD, Endocalyx and placebo) of measured capillary densities, the capillary density in the total cohort was lower when compared to our earlier published Framingham risk groups in the Netherlands Epidemiology of Obesity (NEO) study (supplemental figure 2) [26]. These results reflect the already poor perfused capillary network in South Asian patients with T2DM, compared to the general Dutch population. As the patients in the placebo group did not receive any dietary restrictions, it was used as a control for both the dietary interventions. Using linear mixed model analysis adjusted for age and sex revealed that besides the perturbed anatomic vascular structures, endothelial health (PBR, as the inverse glycocalyx dimension) and overall microvascular health score ($\text{MVHS}_{\text{dynamic}}$) worsened over time in the placebo group (table 2, supplemental figure 3A and supplemental table 1) [27].

FMD effect on microvascular health

During the monthly 5-day diet cycle, daily glucose measurements (self-measurement) resulted in 2 reported occurrences of hypoglycemia (<4.0 mmol/L) upon continued use of SU-derivates or long acting insulin, of which one patient discontinued due this occurrence of hypoglycemia. Overall, patients experienced less of the time the feeling of hyper- or hypoglycemia after the diet cycles (DTSQ questionnaire, supplemental table 2). On day 5 of the first diet cycle, in only 3 of 15 patients, ketone bodies could be detected in urine and in 5 patients (of 13) capillary ketone levels of ≥ 0.5 mmol/L (ketosis) were detected.

Intention to treat analysis using linear mixed model analysis adjusted for age, sex, microvascular or macrovascular complications at baseline and hypertension revealed that after 3 months of recurrent FMD, 3 weeks after last cycle, only $\text{PBR}_{\text{dynamic}}$ significantly increased (estimated mean difference $0.32 \mu\text{m}$ (95% CI $0.18 - 0.50$; table 2). Treatment effects between FMD and placebo groups revealed significant differences within 3 months for $\text{CBV}_{\text{dynamic}}$, $\text{PBR}_{\text{static}}$ and $\text{MVHS}_{\text{dynamic}}$ (table 2). This was also shown with the per protocol analysis showing the delta differences in microvascular parameters between FMD and placebo in figure 2.

Table 2. Differences between baseline and after 3 months in the interventions groups and treatment effects

	Placebo			Diet			Supplement			Treatment effect supplement ²
	Baseline (n=16)	3 months (n=15)	Difference [95% CI] ¹	Baseline (n=18)	3 months (n=13)	Difference [95% CI] ¹	Baseline (n=19)	3 months (n=17)	Difference [95% CI] ¹	
Microvascular parameters										
Capillary density (4-6) (μm/mm ²)	43 (6)	34 (4)	-9 [-23;4]	32 (6)	24 (4)	-7 [-20;6]	32 (5)	35 (3)	3 [-10;15]	0.11
Capillary blood volume static (pL/mm ³)/10 ³ μm ³	12.7 (1.7)	9.9 (1.1)	-2.8 [-6.8;1.3]	10.1 (1.7)	8.1 (1.2)	-2.1 [-6.1;2.0]	10 (1.5)	10.9 (1)	1.0 [-2.8;4.7]	0.10
Capillary blood volume dynamic (pL/mm ²)/10 ³ μm ³	21.6 (2.5)	11.3 (1.4)	-10.3 [-16.2;-4.3]	11.8 (2.5)	14 (1.6)	2.2 [-3.7;8.1]	14.7 (2.3)	13.9 (1.3)	-0.8 [-6.2;4.7]	0.01
PBR static (μm)	2.08 (0.05)	2.24 (0.05)	0.16 [0.03;0.28]	2.26 (0.05)	2.2 (0.06)	-0.05 [-0.19;0.08]	2.21 (0.04)	2.18 (0.05)	-0.04 [-0.16;0.08]	0.01
PBR dynamic (μm)	2.19 (0.05)	2.46 (0.05)	0.28 [0.15;0.40]	2.35 (0.05)	2.66 (0.06)	0.32 [0.18;0.50]	2.74 (0.04)	2.01 (0.05)	-0.73 [-0.85;-0.61]	<0.001
MVHS dynamic (μm)	3.9 (0.5)	1.8 (0.3)	-2.1 [-3.2;-1.1]	2.1 (0.5)	2.1 (0.3)	0 [-1.0;1.1]	2.2 (0.4)	2.8 (0.2)	0.7 [-0.3;1.7]	<0.001
Clinical parameters										
Systolic blood pressure (mmHg)	132 (4)	136 (4)	4 [-5;13]	141 (4)	134 (4)	-7 [-16;3]	133 (3)	130 (3)	-3 [-11;5]	0.17
Diastolic blood pressure (mmHg)	82 (2)	82 (2)	1 [-5;6]	81 (2)	80 (2)	-2 [-7;4]	80 (2)	81 (2)	1 [-4;5]	0.95
BMI (kg/m ²)	26.4 (1.3)	26.4 (1.2)	0 [-0.5;0.4]	28.3 (1.3)	27.3 (1.3)	-1.0 [-1.5;-0.5]	30.2 (1.1)	30.3 (1.1)	0.1 [-0.3;0.6]	0.53
Laboratory markers										
Fasting glucose (mmol/L)	7.3 (0.5)	7.1 (0.6)	-0.1 [-1.4;1.1]	7.2 (0.5)	7.1 (0.6)	-0.2 [-1.5;1.1]	8.3 (0.4)	8.1 (0.5)	-0.2 [-1.3;1]	0.98
Hba1c (mmol/mol)	55.6 (3.3)	55.9 (3)	0.4 [-3.9;4.6]	55.3 (3.4)	50.3 (3.3)	-5.1 [-9.6;-0.6]	57.9 (2.9)	60.2 (2.7)	2.3 [-1.7;6.3]	0.41

Table 2. Differences between baseline and after 3 months in the interventions groups and treatment effects (continued)

	Placebo			Diet			Supplement			Treatment effect supplement ²
	Baseline (n=16)	3 months (n=15)	Difference [95% CI] ¹	Baseline (n=18)	3 months (n=13)	Difference [95% CI] ¹	Baseline (n=19)	3 months (n=17)	Difference [95% CI] ¹	
C-peptide (nmol/L)	1.2 (0.1)	1.2 (0.1)	0 [-0.2;0.2]	1.4 (0.1)	1.3 (0.1)	-0.1 [-0.3;0.1]	1.5 (0.1)	1.5 (0.1)	0.1 [-0.1;0.2]	0.62
eGFR CKD-EPI (ml/min/1.73m ²)	86 (5)	84 (5)	-2 [-8;5]	83 (5)	81 (5)	-2 [-9;5]	80 (4)	83 (4)	3 [-2;9]	0.16
Total cholesterol (mmol/L)	4.03 (0.23)	4.12 (0.26)	0.09 [-0.33;0.51]	4.34 (0.24)	4.21 (0.28)	-0.13 [-0.58;0.32]	4.35 (0.2)	4.34 (0.23)	0 [-0.39;0.38]	0.68
HDL-cholesterol (mmol/L)	1.27 (0.08)	1.35 (0.09)	0.08 [-0.01;0.18]	1.22 (0.08)	1.23 (0.09)	0.01 [-0.09;0.11]	1.08 (0.07)	1.07 (0.08)	-0.01 [-0.09;0.08]	0.10
LDL-cholesterol (mmol/L)	2.34 (0.2)	2.32 (0.2)	-0.02 [-0.33;0.29]	2.4 (0.21)	2.31 (0.21)	-0.09 [-0.42;0.24]	2.41 (0.18)	2.43 (0.18)	0.02 [-0.27;0.31]	0.80
Triglycerides (mmol/L)	1.11 (0.5)	1.19 (0.33)	0.07 [-0.6;0.75]	1.65 (0.5)	1.77 (0.35)	0.12 [-0.56;0.8]	2.31 (0.45)	2.09 (0.29)	-0.22 [-0.84;0.4]	0.43
hsCRP (mg/L)	4.0 (1.1)	3.0 (1.0)	-1.1 [-2.8;0.6]	3.6 (1.1)	2.9 (1.1)	-0.7 [-2.4;1.1]	6.0 (1.0)	6.2 (0.9)	0.2 [-1.3;1.8]	0.16
IGF-1 (nmol/L)	18.3 (1.3)	17.9 (1.2)	-0.4 [-2.6;1.8]	17.9 (1.4)	19.6 (1.3)	1.6 [-0.7;3.9]	17.1 (1.2)	16.5 (1.1)	-0.6 [-2.7;1.4]	0.82

Abbreviations: PBR perfused boundary region, MVHS microvascular health score, BMI body mass index, HDL high density lipoprotein, LDL low density lipoprotein, Hba1c hemoglobin A1c, eGFR CKD-EPI estimated glomerular filtration rate according to chronic kidney disease epidemiology collaboration, hsCRP high sensitivity c-reactive protein, IGF-1 Insulin growth factor 1, ns non-significant; Estimated marginal means with standard error

¹Linear mixed models adjusted for age, sex, microvascular history at baseline, macrovascular history at baseline and hypertension at baseline with Bonferroni post-hoc, baseline compared to 3 months, ²interaction term of the groups with measurement over time (Baseline-3 months), p<0.05 is considered significant (bold).




Figure 2. Changes in microvascular parameters upon FMD treatment. Comparison of changes within 3 months intervention between the diet and placebo group of (A) Capillary density, (B) Dynamic capillary blood volume (CBV_{dynamic}) and (C) Static perfusion boundary region (PBR_{static}), (D) Scatter dot plots and simple linear regression (slope) with 95% confidence intervals of PBR_{static} plotted against red blood cell velocity (VRBC) in feed vessels. Comparison of changes after 3 months intervention between diet (continuous line) and placebo (dashed line) of (E) dynamic perfusion boundary region (PBR_{dynamic}) and (F) dynamic Microvascular Health Score (MVHS_{dynamic}). Box plot whiskers indicate 5th and 95th percentiles. Delta changes were compared between the diet and placebo group with an unpaired t-test. *P < 0.05, **P < 0.01

While BP, fasting glucose, hsCRP and cholesterol levels were not affected after the diet cycles, mean BMI and serum HbA1c levels were significantly lower compared to baseline with an estimated difference of $-1.0 \text{ kg}/\text{m}^2$ (95% CI $-1.5 - -0.5$) and $-5.1 \text{ nmol}/\text{L}$ (95% CI $-9.6 - -0.6$), respectively. Markers related to glycocalyx degradation (HPSE-1) and endothelial and glycocalyx shedding markers (ANG2 and sTM) were not affected (table 3).

The follow-up measurements at month 6 revealed that BMI was still lower compared to baseline, with a difference of $-0.6 \text{ kg}/\text{m}^2$ (95% CI $-1.2 - 0.00$). However, the effect on HbA1c was lost after 6 months compared to baseline with a difference of $-1.8 \text{ mmol}/\text{mol}$ (95% CI $-6.2 - 2.8$) (supplemental table 1). In contrast, PBR_{dynamic} was increased with a positive linear regression slope (supplemental figure 3B) arguing for a continued adverse effect on endothelial function.

Table 3. Differences between baseline and after 3 months in the interventions groups and treatment effects

	Placebo			Diet			Supplement			Treatment effect supplement ²
	Baseline (n=16)	3 months (n=15)	Difference [95% CI] ¹	Baseline (n=18)	3 months (n=13)	Difference [95% CI] ¹	Baseline (n=19)	3 months (n=17)	Difference [95% CI] ¹	
Glycocalyx plasma markers										
HPSE-1 activity plasma (U/mL)	1.04 (0.16)	1.54 (0.19)	0.50 [-0.01;1.00]	1.33 (0.17)	1.46 (0.21)	0.12 [-0.41;0.65]	1.27 (0.14)	1.54 (0.17)	0.28 [-0.18;0.74]	0.43
HYAL-1 activity (U/mL)	0.56 (0.02)	0.54 (0.01)	-0.01 [-0.06;0.03]	N/A	N/A	N/A	0.48 (0.02)	0.52 (0.01)	0.04 [-0.01;0.07]	N/A
HYAL-4 activity (U/mL)	25.10 (2.92)	21.47 (2.6)	-3.63 [-8.78;1.52]	N/A	N/A	N/A	17.82 (2.51)	17.55 (2.17)	-0.27 [-4.87;4.33]	0.23
HYAL-4 protein (ng/mL)	3.45 (0.41)	3.51 (0.39)	0.07 [-0.27;0.41]	N/A	N/A	N/A	2.79 (0.35)	2.61 (0.33)	-0.17 [-0.48;0.13]	0.19
ANG-2 protein (ng/mL)	2.47 (0.24)	2.40 (0.21)	-0.06 [-0.39;0.27]	2.77 (0.24)	2.59 (0.23)	-0.18 [-0.51;0.16]	2.82 (0.21)	3.04 (0.18)	0.22 [-0.08;0.52]	0.12
sTM protein (ng/mL)	5.13 (0.60)	5.80 (0.69)	0.67 [-0.16;1.50]	5.37 (0.62)	5.25 (0.72)	-0.12 [-1.00;0.76]	6.57 (0.52)	6.79 (0.60)	0.22 [-0.53;0.98]	0.33
Urinary markers										
ACR urine (mg/mmol)	3.1 (2.1)	2.6 (0.7)	-0.5 [-5.5;4.4]	2.7 (2.0)	1 (0.8)	-1.7 [-6.4;3.0]	5.0 (1.9)	2.4 (0.6)	-2.6 [-7.2;1.9]	0.44
HPSE-1 activity urine (U/mL)	0.96 (0.19)	0.81 (0.14)	-0.15 [-0.53;0.24]	1.19 (0.21)	0.89 (0.16)	-0.30 [-0.71;0.12]	0.87 (0.17)	0.83 (0.13)	0.04 [-0.40;0.2]	0.62
MCP-1 activity urine (ng/mmol)	22.3 (9.7)	39.3 (8.6)	17.1 [-10.2;44.3]	36.6 (9.3)	28.5 (9.4)	-8.10 [-35.7;19.5]	39.3 (8.7)	25.9 (7.8)	-13.4 [-38.3;11.5]	0.05

Abbreviations: HPSE-1 heparanase-1, HYAL-1 hyaluronidase-1, HYAL-4 hyaluronidase-4, ANG-2 Angiopoietin-2, sTM soluble thrombomodulin, ACR albumin creatinine ratio, MCP-1 monocyte chemoattractant protein 1, *ns* non-significant; Estimated marginal means with standard error

¹Linear mixed models adjusted for age, sex, microvascular complications at baseline and hypertension at baseline with Bonferroni post-hoc, baseline compared to 3 months, ²interaction term of the groups with measurement over time (Baseline-3 months), *p*<0.05 is considered significant (bold).

Endocalyx effects on microvascular health

After 3 months of daily supplementation with Endocalyx, a significant improvement in the $PBR_{dynamic}$ (estimated difference of $-0.73 \mu m$; 95% CI $-0.85 - -0.61$) and $MVHS_{dynamic}$ of 0.7 points (95% CI $-0.3 - 1.7$) was seen, while capillary density, CBV and PBR_{static} did not change significantly (table 2). Treatment effects between Endocalyx and placebo groups for the intention to treat and per protocol analysis showed to be significant for $CBV_{dynamic}$, PBR_{static} , $PBR_{dynamic}$ and $MVHS_{dynamic}$ confirming an overall improvement in vascular health after 3 months of glycocalyx mimetics supplementation (figure 3 and table 2). The follow-up measurements at month 6 revealed a continuation in improved microvascular health (supplemental figure 3C and supplemental table 1).

Markers related to glycocalyx degradation (HPSE-1, HYAL-1 and HYAL-4) and endothelial and glycocalyx shedding markers (ANG2 and sTM), however, were not affected (table 3). Overall, ACR did not significantly change (estimated difference of -2.6 mg/mmol , 95% CI $-7.2 - 1.9$), although in two patients with the highest baseline ACR (28.8 and 37.7 mg/mmol , respectively) albuminuria decreased to normo-albuminuric levels after 3 months of Endocalyx. Urinary MCP-1 activity did not significantly change within 3 months (estimated




Figure 3. Changes in microvascular parameters upon supplement treatment. Comparison of changes within 3 months intervention between the supplement and placebo of (A) Capillary density, (B) Dynamic capillary blood volume ($CBV_{dynamic}$) and (C) Static perfusion boundary region (PBR_{static}), (D) Scatter dot plots and simple linear regression (slope) with 95% confidence intervals of PBR_{static} plotted against red blood cell velocity ($VRBC$) in feed vessels. Comparison of changes after 3 months intervention between supplement (continuous line) and placebo (dashed line) of (E) dynamic perfusion boundary region ($PBR_{dynamic}$) and (F) dynamic Microvascular Health Score ($MVHS_{dynamic}$). Box plot whiskers indicate 5th and 95th percentiles. Delta changes were compared between the supplement and placebo group with an unpaired t-test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.0001$.

difference of -13.4 ng/mmol with 95% CI -38.3 – 11.5), although compared to placebo urinary MCP-1 activity was significantly lower in the supplement group ($p=0.05$) (table 3). No significant changes in other clinical or laboratory parameters were observed (table 2).

Discussion

We evaluated the effect of two short-term dietary interventions on microvascular endothelial health in SA-T2DM. Overall, we found that capillary density in this patient population was already lower than expected compared to earlier measurements within the NEO study [26], and seems in line with the observed existing cardiovascular problems these patients are facing [3]. We also observed in the placebo that during the first 3 months microvascular parameters worsened.

After 3 recurrent FMD cycles, $PBR_{dynamic}$ alone increased, which continued to worsen at 3 months after the last diet cycle. We observed a significant reduction in plasma HbA1c levels and BMI in the first 3 months and the effect on BMI was still present after discontinuation of the FMD cycles.

Supplementation with Endocalyx for 3 months, however, showed an improvement in the microvascular parameters $CBV_{dynamic}$, PBR_{static} , $PBR_{dynamic}$ and $MVHS_{dynamic}$ which was also reflected in the linear regression slopes (PBR_{static} vs. V_{RBC}). Even 3 months after the intervention this effect was still present, indicating a possible legacy effect. Interestingly, we found improvement of albuminuria in 2 patients in this group which was accompanied by an improved PBR. The observed significantly reduced urinary MCP-1 activity after 3 months, however, was lost at follow-up. No effect on the other clinical or laboratory markers were observed upon Endocalyx supplementation.

Although in early diabetic nephropathy inhibition of HPSE-1 activity has been shown to protect the endothelial glycocalyx and to prevent development of proteinuria [15, 36], we could not demonstrate this effect in the present study. Following this study, we recently observed ethnic differences in urinary HPSE-1 and MCP-1 activity in individuals with T2DM from the HELIUS study [37]. Interestingly, the South-Asian Surinamese participants showed the lowest urinary HPSE-1 activity. Urinary HPSE-1 activity in that study was only statistically significant in participants of Dutch origin in relation to ACR.

Previous diet intervention studies in patients with type 2 diabetes revealed reduced BMI, blood pressure, fasting glucose, total and low density cholesterol, CRP and IGF-1 levels in a cohort of 100 participants, particularly in those at risk for disease [38, 39, 40]. We recently showed in an experimental diabetic study, that a repeated FMD was able to

partially preserve glomerular endothelial glycocalyx coverage, however, perturbing glomerular metabolic responses resulting in increased oxidative stress and reduced catabolic breakdown products [23]. While capillary loop morphology and endothelial glycocalyx heparan sulfate contents was preserved, hyaluronan surface expression was reduced which coincided with reduced UDP-glucuronic acid, a rate limiting building block in its biosynthesis. Despite the positive effects in the first FMD trial in patients with T2DM [22], showing beneficial effects on albuminuria levels in patients with micro-albuminuria next to beneficial effects on HbA1c levels and BMI, the lack of improvement in inflammatory or glycocalyx degrading markers in our study could be due to the already established cardiovascular problems, such as retinopathy, neuropathy and other cardiovascular disease markers. These cardiovascular comorbidities, however, do not seem to correspond with the observed albuminuria and these observations argue for alternative disease biomarkers in this specific patient population.

The main risk of severe calorie restriction in patients with diabetes is hypoglycemia and several studies on fasting regimes in T2DM patients emphasize the importance of adjusting the dosage of glucose lowering medications during fasting days [38, 41]. In our study, the dosages of the sulfonylurea derivatives and insulins were changed or stopped during the 5-day fasting cycle to minimize the chance of hypoglycemia. This resulted still in 2 reported occurrences of hypoglycemia during the FMD cycles while patients did experience less of the time the feeling of hyper- or hypoglycemia after the diet cycles (see supplemental data). It appears that, when medication dosage is adapted appropriately and patients are frequently monitored, a low caloric diet can be used safely in patients using sulfonylurea derivatives or insulin.

In one patient, the estimated glomerular filtration rate, which was not routinely measured in this study, turned out to be seriously deteriorated after the first diet cycle. This decline of kidney function appeared to be due to dehydration, as the kidney function fully recovered after intravenous fluid therapy (supplemental data). It has been known for a long time that severe calorie restriction is accompanied by loss of sodium and body water via a largely unexplained mechanism [42, 43]. Therefore, people who fast or use a FMD should always be encouraged to drink sufficiently. In our experimental study, we also found that weight loss during the FMD was mainly due to loss of water and lean mass [23]. Currently, a clinical trial with this diet in patients with diabetes is investigating the effect on body composition by collecting MRI data after a diet cycle [44]. For now, it might be advised that FMD should be used with caution in patients with decreased kidney function or CKD and in patients using diuretics, where kidney function should be monitored regularly.

This study has several limitations. Firstly, the low sample size and drop-out rate of the study. We experienced a low response rate in patients that were contacted for the clinical

study. Conducting lifestyle intervention studies in the South-Asian population has been proven to be extremely difficult due to low response rates, high drop-out rates and lack of effect on lifestyle [45, 46]. We experienced a drop-out rate of 30% in the diet group, comparable to other FMD studies [40]. In addition, due to the COVID-19 epidemic, inclusions of the study had to be discontinued. The low sample size may have reduced the power to show significant effects in the intervention groups although still clear primary endpoints were observed. Secondly, in only a few patients after the FMD cycle, capillary or urinary ketone levels were elevated reflecting ketosis. During fasting, when glycogen stores are depleted and glucose is less available, fatty acids are released from adipose tissue to serve as an alternative fuel, and excessive oxidation of fatty acids is accompanied by ketogenesis. These patients may not have been compliant with the dietary regime. Another explanation, however, could be that the switch from carbohydrate to lipid oxidation in response to fasting is impaired in South-Asians (as compared to European) with T2DM, reflecting metabolic inflexibility in South-Asian individuals [47]. As ketones are probably involved in the health effects of fasting [48], this may indicate that the benefits of fasting or fasting mimicking diets are less effective in individuals from South-Asian descent than in individuals of European descent.

A strength of the study is its execution in general practitioner offices with South-Asian Surinamese patients, a patient group that can be difficult to recruit for clinical trials as mentioned above. An intensive 1 and 2 year targeted lifestyle intervention in general practice revealed no significant weight loss or improvement in metabolic profiles in South-Asian Surinamese participants in The Hague [45, 46]. Although we also experienced low response rates and drop-outs, we did see beneficial effects on BMI and HbA1c levels, already at short term which suggest that South-Asian individuals may find it easier to adhere to repeated short term fasting cycles than continuous caloric restriction or continuous lifestyle interventions.

The development of diabetic vascular complications is a multifactorial pathway, therefore, therapies that target different factors in the pathogenesis are strongly recommended for treatment of diabetes [49]. Preserving endothelial function is seen as a valuable pharmacological target for protecting the microvasculature and reducing the incidence of complications in patients with diabetes [50, 51]. In the present study, we showed that supplementation with Endocalyx™ is a potential candidate able to improve microvascular health in SA-T2DM. We failed to demonstrate direct beneficial microvascular effects of FMD but saw temporarily improvement of metabolic risk factors in SA-T2DM. We confirm that FMD can probably be safely used in patients with diabetes glucose lowering drugs if the dose of these medications are adapted appropriately, but it needs to be used with caution in patients with CKD until further studies has been done.

References

1. Zheng, Y., S.H. Ley, and F.B. Hu, *Global aetiology and epidemiology of type 2 diabetes mellitus and its complications*. Nat Rev Endocrinol, 2018. **14**(2): p. 88-98.
2. Misra, R., et al., *Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study*. J Diabetes Complications, 2010. **24**(3): p. 145-53.
3. Mather, H.M., N. Chaturvedi, and J.H. Fuller, *Mortality and morbidity from diabetes in South Asians and Europeans: 11-year follow-up of the Southall Diabetes Survey, London, UK*. Diabet Med, 1998. **15**(1): p. 53-9.
4. Karter, A.J., et al., *Ethnic disparities in diabetic complications in an insured population*. JAMA, 2002. **287**(19): p. 2519-27.
5. Tillin, T., et al., *The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study*. J Am Coll Cardiol, 2013. **61**(17): p. 1777-86.
6. Swerdlow, A.J., et al., *Mortality of South Asian patients with insulin-treated diabetes mellitus in the United Kingdom: a cohort study*. Diabet Med, 2004. **21**(8): p. 845-51.
7. Qiao, Q., et al., *Age- and sex-specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts*. Diabetes Care, 2003. **26**(6): p. 1770-80.
8. Chandie Shaw, P.K., et al., *Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands*. Diabetologia, 2002. **45**(3): p. 337-41.
9. Barnett, A.H., et al., *Type 2 diabetes and cardiovascular risk in the UK south Asian community*. Diabetologia, 2006. **49**(10): p. 2234-46.
10. Schachinger, V., M.B. Britten, and A.M. Zeiher, *Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease*. Circulation, 2000. **101**(16): p. 1899-906.
11. Suwaidi, J.A., et al., *Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction*. Circulation, 2000. **101**(9): p. 948-54.
12. Pomin, V.H., *Sulfated glycans in inflammation*. Eur J Med Chem, 2015. **92**: p. 353-69.
13. Zaporozhets, T. and N. Besednova, *Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review*. Pharm Biol, 2016. **54**(12): p. 3126-3135.
14. Schalkwijk, C.G. and C.D. Stehouwer, *Vascular complications in diabetes mellitus: the role of endothelial dysfunction*. Clin Sci (Lond), 2005. **109**(2): p. 143-59.
15. Rabelink, T.J., et al., *Heparanase: roles in cell survival, extracellular matrix remodelling and the development of kidney disease*. Nat Rev Nephrol, 2017. **13**(4): p. 201-212.
16. Brandhorst, S., et al., *A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan*. Cell Metab, 2015. **22**(1): p. 86-99.
17. Longo, V.D. and M.P. Mattson, *Fasting: molecular mechanisms and clinical applications*. Cell Metab, 2014. **19**(2): p. 181-92.
18. Varady, K.A., et al., *Clinical application of intermittent fasting for weight loss: progress and future directions*. Nat Rev Endocrinol, 2022. **18**(5): p. 309-321.
19. Choi, I.Y., et al., *A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms*. Cell Rep, 2016. **15**(10): p. 2136-2146.
20. Vernieri, C., et al., *Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer*. Cancer Discov, 2022. **12**(1): p. 90-107.

21. de Groot, S., et al., *The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study*. BMC Cancer, 2015. **15**: p. 652.
22. Sulaj, A., et al., *Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study*. J Clin Endocrinol Metab, 2022.
23. van der Velden, A.I.M., et al., *Fasting mimicking diet in diabetic mice partially preserves glomerular endothelial glycocalyx coverage, without changing the diabetic metabolic environment*. Am J Physiol Renal Physiol, 2024.
24. Regier, M., et al., *A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum*. Int J Mol Sci, 2022. **23**(24).
25. Yuan, L., et al., *Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit*. ERJ Open Res, 2022. **8**(2).
26. van der Velden, A.I.M., et al., *Microvascular differences in individuals with obesity at risk of developing cardiovascular disease*. Obesity (Silver Spring), 2021. **29**(9): p. 1439-1444.
27. Rovas, A., et al., *Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study*. Crit Care, 2021. **25**(1): p. 112.
28. Levey, A.S., et al., *A new equation to estimate glomerular filtration rate*. Ann Intern Med, 2009. **150**(9): p. 604-12.
29. Bradley, C., *Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur*. Diabetes Care, 1999. **22**(3): p. 530-2.
30. Friedewald, W.T., R.I. Levy, and D.S. Fredrickson, *Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge*. Clin Chem, 1972. **18**(6): p. 499-502.
31. Honda, T., et al., *Hyaluronidases Have Strong Hydrolytic Activity toward Chondroitin 4-Sulfate Comparable to that for Hyaluronan*. Biomolecules, 2012. **2**(4): p. 549-63.
32. Kaneiwa, T., et al., *Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence*. Glycobiology, 2010. **20**(3): p. 300-9.
33. Buijsers, B., et al., *Increased Plasma Heparanase Activity in COVID-19 Patients*. Front Immunol, 2020. **11**: p. 575047.
34. Lee, D.H., et al., *Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion*. PLoS One, 2014. **9**(5): p. e96477.
35. Rovas, A., et al., *Bedside analysis of the sublingual microvascular glycocalyx in the emergency room and intensive care unit - the GlycoNurse study*. Scand J Trauma Resusc Emerg Med, 2018. **26**(1): p. 16.
36. Dogne, S., et al., *Hyaluronidase 1 Deficiency Preserves Endothelial Function and Glycocalyx Integrity in Early Streptozotocin-Induced Diabetes*. Diabetes, 2016. **65**(9): p. 2742-53.
37. van der Velden, A.I.M., et al., *Ethnic differences in urinary monocyte chemoattractant protein-1 and heparanase-1 levels in individuals with type 2 diabetes: the HELIUS study*. BMJ Open Diabetes Res Care, 2022. **10**(6).
38. Carter, S., P.M. Clifton, and J.B. Keogh, *The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial*. Diabetes Res Clin Pract, 2016. **122**: p. 106-112.

39. Ash, S., et al., *Effect of intensive dietetic interventions on weight and glycaemic control in overweight men with Type II diabetes: a randomised trial*. *Int J Obes Relat Metab Disord*, 2003. **27**(7): p. 797-802.
40. Wei, M., et al., *Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease*. *Sci Transl Med*, 2017. **9**(377).
41. Corley, B.T., et al., *Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial*. *Diabet Med*, 2018. **35**(5): p. 588-594.
42. Kreitzman, S.N., A.Y. Coxon, and K.F. Szaz, *Glycogen storage: illusions of easy weight loss, excessive weight regain, and distortions in estimates of body composition*. *Am J Clin Nutr*, 1992. **56**(1 Suppl): p. 292S-293S.
43. Heyman, S.N., et al., *Fasting-Induced Natriuresis and SGLT: A New Hypothesis for an Old Enigma*. *Front Endocrinol (Lausanne)*, 2020. **11**: p. 217.
44. van den Burg, E.L., et al., *Fasting in diabetes treatment (FIT) trial: study protocol for a randomised, controlled, assessor-blinded intervention trial on the effects of intermittent use of a fasting-mimicking diet in patients with type 2 diabetes*. *BMC Endocr Disord*, 2020. **20**(1): p. 94.
45. Admiraal, W.M., et al., *Intensive lifestyle intervention in general practice to prevent type 2 diabetes among 18 to 60-year-old South Asians: 1-year effects on the weight status and metabolic profile of participants in a randomized controlled trial*. *PLoS One*, 2013. **8**(7): p. e68605.
46. Vlaar, E.M.A., et al., *Effectiveness of a targeted lifestyle intervention in primary care on diet and physical activity among South Asians at risk for diabetes: 2-year results of a randomised controlled trial in the Netherlands*. *BMJ Open*, 2017. **7**(6): p. e012221.
47. Bakker, L.E., et al., *Middle-aged overweight South Asian men exhibit a different metabolic adaptation to short-term energy restriction compared with Europeans*. *Diabetologia*, 2015. **58**(1): p. 165-77.
48. Kolb, H., et al., *Ketone bodies: from enemy to friend and guardian angel*. *BMC Med*, 2021. **19**(1): p. 313.
49. Verspohl, E.J., *Novel pharmacological approaches to the treatment of type 2 diabetes*. *Pharmacol Rev*, 2012. **64**(2): p. 188-237.
50. Hink, U., et al., *Mechanisms underlying endothelial dysfunction in diabetes mellitus*. *Circ Res*, 2001. **88**(2): p. E14-22.
51. Potenza, M.A., et al., *Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets*. *Curr Med Chem*, 2009. **16**(1): p. 94-112.

Supplemental data

Effect of the fasting mimicking diet, continued

In all patients except one, HbA1c levels decreased after the FMD cycles compared to baseline levels. In 2 patients, dosages of anti-diabetic medication were lowered in the 3 month intervention period due to improved fasting glucose levels. In 2 patients (one patient of which HbA1c levels did not decrease), the dosage of anti-diabetic medication was increased by the GP (data not shown). The change in BMI and HbA1c between the FMD and placebo group was significantly different as shown by the treatment effects (table 2).

IGF-1 levels did not change after 3 FMD cycles (table 2). Most likely because the study visit took place 3 weeks after the last FMD cycle at the end of 3 month study, resulting in IGF-1 levels already returned to baseline [1]. Furthermore, plasma levels of angiopoietin-2 (ANG2) and soluble thrombomodulin (sTM), and heparanase-1 (HPSE-1) activity, all markers of endothelial activation and glycocalyx degradation did not change after 3 months of FMD cycles (table 2). Nor did the urinary markers such as the ACR, urinary HPSE-1 and MCP-1 activity levels decrease significantly after 3 FMD cycles (table 2).

FMD treatment satisfaction

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) [2] which was developed to assess the diabetes treatment satisfaction and consists of eight items, each rated on a seven-point scale. The items include satisfaction with current treatment, treatment convenience, flexibility of treatment, understanding of diabetes, continuity of treatment, recommending treatment to others and two additional items about perceived frequency of hyper- and hypoglycemia. The DTSQ static (DTSQs) was conducted at baseline and the items range from 6 (very satisfied) to 0 (very dissatisfied) with the sum of scores ranging from 36 to 0. The perceived frequency of hyper- and hypoglycemia were also scored from 0 (none of the time) to 6 (most of the time). The DTSQ change (DTSQc) was conducted after 3 months of the intervention. DTSQc uses the same eight items as the DTSQs, but assess changes in the treatment satisfaction with their current treatment (intervention) compared to their previous treatment. The items are scored from +3 (much more satisfied now) to -3 (much less satisfied now), with 0 representing no change. The sum of the score thus ranges from 18 to -18. The perceived frequency of hyper- and hypoglycemia are also scored from +3 (much more of the time now) to -3 (much less of the time now).

In both the FMD and placebo group, satisfaction with their current diabetes treatment at the general practitioners office at baseline was high, with a mean DTSQ satisfaction score of 30.3 ($\pm$ 5.0) in the FMD group and 30.2 ($\pm$ 4.4) in the placebo group (supplemental table 1). Perceived frequency of hyperglycemia was comparable between both groups as baseline, with a mean score of 2.9 ($\pm$ 1.7) in the FMD group and 2.9 ($\pm$ 2.2) in the placebo

group. Perceived frequency of hypoglycemia was also comparable between both groups, with a mean score of 1.8 ($\pm$ 2.0) in the FMD group and 1.6 ($\pm$ 2.0) in the placebo group.


After the 3 FMD cycles, mean treatment satisfaction score with the DTSQc was 11.3 ($\pm$ 4.5), indicating more satisfaction with the intervention compared to the baseline anti-diabetic medication. The placebo group received placebo capsules for 3 months and were also more satisfied with the intervention, with a mean DTSQc treatment satisfaction score of 10.1 ($\pm$ 7.5). However, perceived hyper- or hypoglycemia did not change in the placebo group with mean scores of 0.1 on both items. After the 3 FMD cycles, mean score of perceived hyperglycemia was -1.0 ($\pm$ 1.5), indicating that these patients had less of the time the feeling of hyperglycemia after the FMD. These patients also had less of the time perceived hypoglycemia, with a mean score of -0.5 ($\pm$ 2.0) on this item after 3 FMD cycles.

Adverse events FMD


The Common Terminology Criteria for Adverse Events (CTCAE) was used to report adverse event during or after the FMD cycles. The most reported adverse events during the FMD cycles were grade 1 (mild) or grade 2 (moderate) symptoms of headache, fatigue, diarrhea and hypoglycemia. Two patients self-reported the occurrence of hypoglycemia during an FMD cycle. A total of 4 patients dropped out during or after the first cycle due to adverse events. In one patient, a SAE occurred. Kidney function acutely deteriorated at day 5 of the first FMD cycle as compared to previous measurements, which was noticed during a routine check at the hospital. The creatinine level at baseline was 125 μ mol/L for this patient, which increased to 169 μ mol/L at day 5 of the FMD and increased even further one week later to 202 μ mol/L. The patient was hospitalized and rehydrated, after which the creatinine levels normalized to baseline values. This patient was withdrawn from the study by the investigator. No negative effects were seen on kidney function 3 weeks after the third FMD cycle (table 2).

References


1. Caputo, M., et al., *Regulation of GH and GH Signaling by Nutrients*. Cells, 2021. **10**(6).
2. Bradley, C., *Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur*. Diabetes Care, 1999. **22**(3): p. 530-2.
3. van der Velden, A.I.M., et al., *Microvascular differences in individuals with obesity at risk of developing cardiovascular disease*. Obesity (Silver Spring), 2021. **29**(9): p. 1439-1444.



Supplemental figure 1. Pilot study to determine minimal sample size necessary. Healthy volunteers were given the food supplement Endocalyx™ for 3 consecutive months (n = 13 final measurements) revealing (A) valid total microvascular density, and (B) overall microvascular health score (MVHS_{dynamic}). Significance over the three month supplementation is given and was performed using one-way ANOVA (+ Geiser-Greenhouse correction) with mixed effects-model and Dunnet multiple comparison test. After 3 months, a 31% improvement in MVHS_{dynamic} was demonstrated, expressed in a significant increase of from 1.05 at baseline, to 1.38 at 3 months (improvement of 0.33). To achieve per group a 80% power to detect a difference of 0.35 between the null hypothesis that group improvement means are 0.0 and the alternative hypothesis that the improvement mean of group 2 or 3 is 0.35 with group standard deviations of 0.41 and a significance level (alpha) of 0.05 (two-sided two-sample t-test) the estimated group sample size is 23.



Supplemental figure 2. Comparison capillary density loss in South Asian patients with T2DM at baseline. Percentage difference in the number of perfused capillaries (capillary density) per capillary diameter group of total South Asian patients with T2DM in current study at baseline (n = 53) and from intermediate- and high-risk Framingham groups (n = 253 or 168, respectively) from the published NEO study [3] were compared to the low-risk Framingham group (as reference, n = 392).



Supplemental figure 3. Changes in linear regression slopes over time. Comparison of linear regression slopes with 95% confidence intervals of PBR_{static} plotted against red blood cell velocity (V_{RBC}) in feed vessels at each consecutive timepoint of (A) placebo, (B) diet (FMD) and (C) supplement (endocalyx) group. Comparison of changes between baseline, after intervention at 3 months and at month 6 (3 months after last intervention).

Supplemental table 1. Differences between baseline and after 6 months and intervention groups in treatment effects.

	Placebo			Diet			Supplement			Treatment effect supplement ²
	Baseline	6 months	Difference [95% CI] ¹	Baseline	6 months	Difference [95% CI] ¹	Baseline	6 months	Difference [95% CI] ¹	
Microvascular parameters										
Capillary density (4-6) (μm/mm ²)	43 (6)	45 (6)	1 [-16;18]	32 (6)	35 (6)	4 [-14;21]	32 (5)	36 (5)	4 [-12;19]	0.80
Capillary blood volume static (pL/mm ²)/10 ³ μm ³	12.7 (1.7)	11.7 (1.5)	-1.0 [-5.7;3.7]	10.1 (1.7)	10.4 (1.6)	0.3 [-4.5;5.0]	10.0 (1.5)	11.0 (1.3)	1.0 [-3.3;5.2]	0.45
Capillary blood volume dynamic (pL/mm ²)/10 ³ μm ³	21.6 (2.5)	13.1 (1.9)	-8.5 [-15.2;-1.8]	11.8 (2.5)	17.3 (2.1)	5.5 [-1.2;12.2]	14.7 (2.3)	14.2 (1.7)	-0.5 [-6.6;5.5]	0.001
PBR static (μm)	2.08 (0.05)	2.24 (0.05)	0.16 [0.01;0.31]	2.26 (0.05)	2.23 (0.06)	-0.03 [-0.18;0.13]	2.21 (0.04)	2.17 (0.05)	-0.05 [-0.19;0.09]	0.04
PBR dynamic (μm)	2.19 (0.05)	2.27 (0.05)	0.08 [-0.07;0.24]	2.35 (0.05)	3.21 (0.05)	0.86 [0.70;1.00]	2.74 (0.04)	2.09 (0.04)	-0.65 [-0.78;-0.51]	<0.01
MVHS dynamic (μm)	3.9 (0.5)	2.2 (0.3)	-1.7 [-2.8;-0.5]	2.1 (0.5)	2.1 (0.3)	0.1 [-1.1;1.2]	2.2 (0.4)	2.7 (0.3)	0.6 [-0.5;1.6]	0.01
Clinical parameters										
Systolic blood pressure (mmHg)	132 (4)	135 (3)	3 [-7;14]	141 (4)	131 (3)	-10 [-21;0]	133 (3)	130 (3)	-3 [-13;7]	0.04
Diastolic blood pressure (mmHg)	82 (2)	85 (2)	3 [-3;9]	81 (2)	78 (2)	-3 [-9;3]	80 (2)	80 (2)	-1 [-6;5]	0.06
BMI (kg/m ²)	26.4 (1.3)	26.4 (1.3)	0 [-0.6;0.5]	28.3 (1.3)	27.8 (1.3)	-0.6 [-1.2;0]	30.2 (1.1)	30 (1.1)	-0.2 [-0.7;0.3]	0.12
Laboratory markers										
Fasting glucose (mmol/L)	7.3 (0.5)	7 (0.6)	-0.3 [-1.4;0.8]	7.2 (0.5)	7.6 (0.6)	0.4 [-0.8;1.6]	8.3 (0.4)	8.1 (0.5)	-0.1 [-1.1;0.9]	0.30
										0.79

Supplemental table 1. Differences between baseline and after 6 months and intervention groups in treatment effects (continued)

	Placebo			Diet			Supplement				
	Baseline (n=16)	6 months (n=15)	Difference [95% CI] ¹	Baseline (n=18)	6 months (n=13)	Difference [95% CI] ¹	Baseline (n=19)	6 months (n=17)	Difference [95% CI] ¹	Treatment effect diet ²	Treatment effect supple- ment ²
HbA1c (%)	55.6 (3.3)	56.9 (3.4)	1.3 [-3.5;6]	55.3 (3.4)	53.6 (3.6)	-1.8 [-6.3;2.8]	57.9 (2.9)	59.2 (3)	1.3 [-2.7;5.2]	0.23	0.98
(mmol/mol)											
C-peptide (nmol/L)	1.2 (0.1)	1.3 (0.2)	0.1 [-0.1;0.3]	1.4 (0.1)	1.5 (0.2)	0.1 [-0.2;0.3]	1.5 (0.1)	1.6 (0.1)	0.1 [-0.1;0.3]	0.83	0.97
eGFR CKD-EPI (ml/ min/1.73m ²)	86 (5)	84 (4)	-2 [-8;4]	83 (5)	84 (4)	1 [-5;7]	80 (4)	82 (4)	2 [-4;7]	0.42	0.27
Total cholesterol (mmol/L)	4.03 (0.23)	4.09 (0.23)	0.06 [-0.38;0.49]	4.34 (0.24)	4.31 (0.25)	-0.03 [-0.48;0.42]	4.35 (0.2)	4.28 (0.2)	-0.07 [-0.46;0.32]	0.73	0.59
HDL-cholesterol (mmol/L)	1.27 (0.08)	1.31 (0.09)	0.05 [-0.06;0.15]	1.22 (0.08)	1.24 (0.09)	0.02 [-0.09;0.13]	1.08 (0.07)	1.06 (0.07)	-0.02 [-0.11;0.08]	0.71	0.28
LDL-cholesterol (mmol/L)	2.34 (0.2)	2.40 (0.18)	0.06 [-0.31;0.44]	2.4 (0.21)	2.22 (0.20)	-0.18 [-0.57;0.21]	2.41 (0.18)	2.32 (0.16)	-0.09 [-0.44;0.26]	0.27	0.46
Triglycerides (mmol/L)	1.11 (0.5)	1.15 (0.33)	0.04 [-0.65;0.73]	1.65 (0.5)	1.84 (0.35)	0.19 [-0.5;0.88]	2.31 (0.45)	2.17 (0.29)	-0.14 [-0.77;0.49]	0.69	0.64
hsCRP (mg/L)	4.0 (1.1)	1.8 (1.2)	-2.3 [-4.9;0.3]	3.6 (1.1)	3.1 (1.3)	-0.5 [-3.1;2.2]	6.0 (1.0)	6.9 (1.0)	0.9 [-1.4;3.2]	0.23	0.03
IGF-1 (nmol/L)	18.3 (1.3)	19.6 (1.4)	1.3 [-1.5;4.2]	17.9 (1.4)	18.7 (1.5)	0.8 [-2.2;3.7]	17.1 (1.2)	17.5 (1.2)	0.4 [-2.2;2.9]	0.72	0.54

Abbreviations: *PBR* perfused boundary region, *MVHS* microvascular health score, *BM*/ body mass index, *HbA1c* hemoglobin A1c, *eGFR CKD-EPI* estimated glomerular filtration rate according to chronic kidney disease epidemiology collaboration, *HDL* high density lipoprotein, *LDL* low density lipoprotein, *hsCRP* high sensitivity c-reactive protein, *IGF-1* Insulin growth factor 1, *ns* non-significant; Estimated marginal means with standard error

¹Linear mixed models adjusted for age, sex, microvascular history at baseline, macrovascular history at baseline and hypertension at baseline with Bonferroni post-hoc, baseline compared to 6 months, ²interaction term of intervention group with measurement over time (Baseline-6 months), *p*<0.05 is considered significant (bold).

Supplemental table 2. Diabetes Treatment Satisfaction Questionnaire

	Placebo	Diet	p-value ¹
Baseline – DTSQ static	n=15	n=17	
Treatment satisfaction score	30.2 (4.4)	30.3 (5.0)	ns
Perceived frequency of hyperglycaemia	2.9 (2.2)	2.9 (1.7)	ns
Perceived frequency of hypoglycaemia	1.6 (2.0)	1.8 (2.0)	ns
Month 3 – DTSQ change	n=15	n=13	
Treatment satisfaction score	10.1 (7.5)	11.3 (4.5)	ns
Perceived frequency of hyperglycaemia	0.1 (1.5)	-1.0 (1.5)	ns
Perceived frequency of hypoglycaemia	0.1 (1.8)	-0.5 (2.0)	ns

Abbreviations: *DTSQ* Diabetes Treatment Satisfaction Questionnaire, *ns* non-significant

¹Unpaired t-test, $P < 0.05$ is considered significant. 1 missing baseline in both diet and placebo group.

Supplemental table 3. Differences between baseline and after 6 months and intervention groups in treatment effects

	Placebo			Diet			Supplement			Treatment effect supplement ²
	Baseline (n=16)	6 months (n=15)	Difference [95% CI] ¹	Baseline (n=18)	6 months (n=13)	Difference [95% CI] ¹	Baseline (n=19)	6 months (n=17)	Difference [95% CI] ¹	
Glycocalyx plasma markers										
HPSE-1 activity, plasma (U/mL)	1.04 (0.16)	0.85 (0.16)	-0.19 [-0.72;0.34]	1.33 (0.17)	1.09 (0.18)	-0.24 [-0.78;0.30]	1.27 (0.14)	1.23 (0.15)	-0.03 [-0.52;0.45]	0.87
HYAL-1 activity (U/mL)	0.56 (0.02)	0.54 (0.02)	-0.02 [-0.06;-0.02]	N/A	N/A	N/A	0.48 (0.02)	0.47 (0.02)	-0.01 [-0.05;-0.02]	N/A
HYAL-4 activity (U/mL)	25.1 (2.92)	21.33 (2.64)	-3.77 [-8.39;0.85]	N/A	N/A	N/A	17.82 (2.51)	15.86 (2.26)	-1.96 [-6.16;2.24]	N/A
HYAL-4 protein (ng/mL)	3.45 (0.41)	3.27 (0.39)	-0.18 [-0.46;0.09]	N/A	N/A	N/A	2.79 (0.35)	2.67 (0.33)	-0.11 [-0.36;0.14]	N/A
ANG-2 protein (ng/mL)	2.47 (0.24)	2.57 (0.27)	0.11 [-0.34;0.56]	2.77 (0.24)	2.94 (0.28)	0.17 [-0.29;0.64]	2.82 (0.21)	3.19 (0.24)	0.36 [-0.05;0.77]	0.81
sTM protein (ng/mL)	5.13 (0.60)	4.29 (0.61)	-0.83 [-1.49;-0.17]	5.37 (0.62)	4.66 (0.64)	-0.71 [-1.38;-0.04]	6.57 (0.52)	5.49 (0.53)	-1.08 [-1.68;-0.48]	0.74
Urinary markers										
ACR, urine (mg/mmol)	3.1 (2.1)	2.8 (0.7)	-0.3 [-5.1;4.6]	2.7 (2.0)	1 (0.8)	-1.7 [-6.3;2.9]	5.0 (1.9)	2.1 (0.6)	-2.9 [-7.4;1.5]	0.59
HPSE-1 activity, urine (U/mL)	0.96 (0.19)	0.55 (0.11)	-0.41 [-0.83;-0.01]	1.19 (0.21)	0.67 (0.13)	-0.52 [-0.95;-0.07]	0.87 (0.17)	0.60 (0.09)	-0.28 [-0.65;0.09]	0.68
MCP-1 activity, urine (ng/mmol)	22.3 (9.7)	20.6 (4.7)	-1.7 [-23.7;20.4]	36.6 (9.3)	28.2 (5.3)	-8.5 [-29.6;12.7]	39.3 (8.7)	25.9 (4.1)	-13.4 [-33.4;6.7]	0.59

Abbreviations: HPSE-1 heparanase-1, HYAL-1 hyaluronidase-1, HYAL-4 hyaluronidase-4, ANG-2 Angiopoietin-2, STM soluble thrombomodulin, ACR albumin creatinine ratio, MCP-1 monocyte chemoattractant protein 1, N/A not applicable, ns non-significant; Estimated marginal means with standard error

¹Linear mixed models adjusted for age, sex, microvascular history at baseline, macrovascular history at baseline and hypertension at baseline with Bonferroni post-hoc, baseline compared to 6 months, ²interaction term of intervention group with measurement over time (Baseline-6 months), p<0.05 is considered significant (bold).